Articles related to DRUG PIPELINE

Blarcamesine (Anavex 2-73), an investigational once-daily oral autophagy enhancer, showed sustained cognitive, functional, and brain volume benefits through nearly 3 years in a Phase 2b/3 trial and open-label extension presented at AD/PD 2026.

FDA priority review vouchers granted to three psychedelic developers and a recent executive order may accelerate regulatory timelines for psilocybin and related compounds, with clinical availability potentially within 12 months pending positive Phase 3 data.

The FDA approved vepdegestrant for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after endocrine therapy progression, marking the first regulatory approval of a PROTAC drug.

Boehringer Ingelheim’s SYNCHRONIZE-1 phase 3 trial reported 16.6% average body weight reduction with survodutide, a dual GLP-1/glucagon receptor agonist, over 76 weeks in adults without type 2 diabetes.

Rodent and non-human primate studies showed glucagon and GIP agonism alone produced weight loss comparable to GLP-1-containing triple agonists in a Bluewater Biosciences-funded program.

A novel oral extended-release minoxidil formulation produced significantly greater non-vellus hair counts and patient-reported coverage improvement than placebo in men with androgenetic alopecia at six months.